Fluconazole + SCY-078
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Candida Vulvovaginitis
Conditions
Candida Vulvovaginitis
Trial Timeline
Aug 1, 2017 → May 4, 2018
NCT ID
NCT03253094About Fluconazole + SCY-078
Fluconazole + SCY-078 is a phase 2 stage product being developed by Scynexis for Candida Vulvovaginitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03253094. Target conditions include Candida Vulvovaginitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03253094 | Phase 2 | Completed |
Competing Products
8 competing products in Candida Vulvovaginitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 33 |
| SHR3680 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Efalizumab | Merck | Approved | 85 |
| AMO959 + Enzalutamide + Abiraterone | Novartis | Phase 1/2 | 41 |
| Clotrimazole 1% (Empecid L Cream, BAYB5097) | Bayer | Pre-clinical | 20 |
| Ibrexafungerp + Placebo | Scynexis | Phase 3 | 69 |
| Ibrexafungerp + Placebo | Scynexis | Phase 3 | 69 |
| hLF1-11 + hLF1-11 + Placebo | AM-Pharma | Phase 1/2 | 33 |